Monte Rosa Therapeutics plans Phase 2 gout trial of MRT-8102 in Q4 2026
GLUE•Monte Rosa Therapeutics expects to start a Phase 2 trial of MRT-8102 in gout patients in the fourth quarter of 2026, with initial data expected in the second half of 2027.
1. Trial plans
The company expects to start GEMINI-1, a Phase 2 trial evaluating whether MRT-8102 can prevent recurrent flares following acute treatment of gout, in the fourth quarter of 2026. Initial data are expected in the second half of 2027.
2. Preclinical findings
Preclinical results showed reduced joint swelling in rabbits with gouty arthritis and suppressed inflammatory activity in human experimental systems. Monte Rosa Therapeutics will present the findings at ACR Convergence on November 9, 2026.
